StockData
Danaher Corp logo

Danaher Corp

DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3027% above fair value
$232.23−4.75 (-2.00%)

Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –

Danaher Cepheid (GeneXpert Molecular Diagnostics) by Quarter

Cepheid (GeneXpert Molecular Diagnostics) — MAUDE Adverse Event Reports

QuarterlyAnnualMonthly

Danaher Cepheid (GeneXpert Molecular Diagnostics): 3 in Q3 2026, down 57.1% from a year earlier.

Latest, Q3 2026
3
Period ended Sep 30, 2026
Change on a year earlier
-57.1%
7 in Q3 2025
History
36 quarters
Since Q1 2017
Sources
1
U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE)

Where the Q3 2026 figure comes from

Source: U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗

Reported in U.S. FDA openFDA MAUDE Adverse Event API.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCepheid (GeneXpert Molecular Diagnostics) — MAUDE Adverse Event ReportsYear on yearSource
Q3 2026Sep 30, 20263-57.1%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2026Jun 30, 20263-62.5%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2026Mar 31, 20263-80.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2025Dec 31, 202513+30.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q3 2025Sep 30, 20257+40.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2025Jun 30, 20258+60.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2025Mar 31, 202515+50.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2024Dec 31, 202410+42.9%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q3 2024Sep 30, 20245-28.6%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2024Jun 30, 20245+150.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2024Mar 31, 202410-23.1%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2023Dec 31, 20237-30.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q3 2023Sep 30, 20237-41.7%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2023Jun 30, 20232-94.3%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2023Mar 31, 202313-80.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2022Dec 31, 202210-76.7%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗

Cite this data

StockData. (2026). Danaher Cepheid (GeneXpert Molecular Diagnostics), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/ext-fda-maude-cepheid

See every metric in the Danaher KPI table. Data updated Nov 2, 2026.